Immedica has an ability to impact sustainability through the different stakeholders forming part of its operations, both in its internal ways of working as well as through the external business partner collaborations. These are summarized in the following commitments:
- We reduce our environmental footprint and work with our suppliers and partners towards a sustainable value chain
- We make sure that employees have a safe and sustainable working environment and help them develop
- We operate with high compliance practice and have zero tolerance for bribery, corruption and forced labor
- By implementing ESG diligence in our business partnering model we contribute to impact our partners’ ESG work
The global climate change is today one of the world’s most pressing challenges. Immedica is committed to take actions to minimize the carbon footprint and other pollution, protect land, water, and natural resources and biodiversity impacted by our own operations as well as to impact our third-party vendors to minimize theirs. These actions are aligned with the intention of the Paris agreement to reduce global warming well below 2°C and pursuing efforts to limit it to 1.5 °C.
Immedica has a major responsibility and ability to impact sustainability through its partnering and procurement processes. Immedica has therefore implemented a framework for how potential new business partners in all areas shall be vetted and to ensure implementation of certain minimum standards in the selection and contracting process. The framework also governs risk assessment, governance of the collaboration, reporting and auditing requirements.
Immedica’s employees are our most important assets for a successful and sustainable business. An employee satisfaction survey is executed on a yearly basis to capture any deviations that may impact on the satisfaction among employees. During 2023 all Immedica employees particpated in the global employee survey Great Place To Work. We had a trust index of 92%, which is a fantastic result. This score also made us number 11 of all mid-sized companies in Sweden and the best company among Pharma and Biotech companies in Sweden.
